Serentis correction
This article was originally published in Scrip
Executive Summary
Serentis has pointed out that it raised a total of £15.3 million, not $15.3 million, and that SRD 174 is an anti-pruritic, not an antipyretic, as reported in Scrip (Online August 13th, 2008).